{
    "URL": "https://doi.org/10.1371/journal.pntd.0004846",
    "Published": "July 13, 2016",
    "Subject_Areas": [
        "Vaccines",
        "Vaccination and immunization",
        "Rabies",
        "Viral vaccines",
        "Guillain-Barre syndrome",
        "Anaphylaxis",
        "Booster doses",
        "Adverse events"
    ],
    "Authors": {
        "Pedro L. Moro": [
            "Immunization Safety Office, Division of Healthcare Quality Promotion (DHQP), National Center for Zoonotic and Emerging Infectious Diseases (NCZEID), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America"
        ],
        "Emily Jane Woo": [
            "Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America"
        ],
        "Wendy Paul": [
            "Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America"
        ],
        "Paige Lewis": [
            "Immunization Safety Office, Division of Healthcare Quality Promotion (DHQP), National Center for Zoonotic and Emerging Infectious Diseases (NCZEID), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America"
        ],
        "Brett W. Petersen": [
            "Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, NCZEID, CDC, Atlanta, Georgia, United States of America"
        ],
        "Maria Cano": [
            "Immunization Safety Office, Division of Healthcare Quality Promotion (DHQP), National Center for Zoonotic and Emerging Infectious Diseases (NCZEID), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America"
        ]
    }
}